If you have been reading about GLP-1 receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
He was also involved in Meeting Se Meeting Tak, an unreleased project. His final major acting role during this period was in Pyaar Impossible!(2010). That same year, he participated as a contestant on the reality television show Khatron Ke Khiladi.
Seven genes encode seven distinct 14-3-3 proteins in most mammals (See Human genes below) and 13–15 genes in many higher plants, though typically in fungi they are present only in pairs. Protists have at least one. Eukaryotes can tolerate the loss of a single 14-3-3 gene if multiple genes are expressed, but deletion of all 14-3-3s (as experimentally determined in yeast) results in death. 14-3-3 proteins are structurally similar to the Tetratrico Peptide Repeat (TPR) superfamily, which generally have 9 or 10 alpha helices, and usually form homo- and/or hetero-dimer interactions along their amino-termini helices. These proteins contain a number of known common modification domains, including regions for divalent cation interaction, phosphorylation & acetylation, and proteolytic cleavage, among others established and predicted. 14-3-3 binds to peptides. There are common recognition motifs for 14-3-3 proteins that contain a phosphorylated serine or threonine residue, although binding to non-phosphorylated ligands has also been reported. This interaction occurs along a so-called binding groove or cleft that is amphipathic in nature. To date, the crystal structures of six classes of these proteins have been resolved and deposited in the public domain.
Somnolence (difficulty staying awake) Mental confusion Hypotension Hypoventilation Impaired motor functions Impaired reflexes Impaired coordination Impaired balance Dizziness Muscle weakness Coma Chlordiazepoxide is typically used under controlled conditions for specific syndromes and sees far less frequent usage when compared to newer drugs of the same class and thus is unlikely to be encountered in a clinical emergency setting as a stand-alone drug causing life-threatening concern. Like other drugs in its class, chlordiazepoxide alongside benzodiazepines as a whole have a lowered potential to cause life-threatening injury - though this does not preclude their common co-contaminant discovery with other depressant drugs of abuse, nor their ability to contribute to an already potentially fatal episode of drug-induced respiratory depression. In cases of suspected overdose, supportive care and observation are most often indicated and provided incrementally in relation to severity and duration of symptoms. Flumazenil is uniquely poised as an "antidote" that specifically counteracts damaging central nervous system affect induced via benzodiazepine mechanism of action - though is not generally indicated in relation to the severity of symptoms where other treatment options exist, and often has numerous damaging consequences that must be carefully weighted before any potential administration.
Sources: en.wikipedia.org
In the Cape Colony, increasing tensions between some Dutch Settlers and the British colonial authorities led to a wave of Boer (also known as Voortrekkers) migration northwards from 1836 onwards in order to establish autonomous Boer states independent of British control. The Boers settlers began moving across the Orange River northwards. While travelling they first collided with the Ndebele kingdom, and then with Dingane's Zulu kingdom. In October 1837, the Voortrekker leader Piet Retief visited Dingane at his royal kraal to negotiate a land deal for the voortrekkers. In November, about 1,000 Voortrekker wagons began descending the Drakensberg mountains from the Orange Free State into what is now KwaZulu-Natal. Dingane asked that Retief and his party retrieve some cattle stolen from him by a local chief as part of the treaty for land for the Boers. This Retief and his men did, returning on 3 February 1838. The next day, a treaty was signed, wherein Dingane ceded all the land south of the Tugela River to the Mzimvubu River to the Voortrekkers. Celebrations followed. On 6 February, at the end of the celebrations, Retief's party were invited to a dance, and asked to leave their weapons behind. At the peak of the dance, Dingane leapt to his feet and yelled "Bambani abathakathi!" (isiZulu for "Seize the wizards"). Retief and his men were overpowered, taken to the nearby hill kwaMatiwane, and executed. Some allege that they were killed for withholding some of the cattle they recovered, but it is likely that the deal was a plot to overpower the Voortrekkers.
Complement proteins are also involved in cartilage transformation. C3, factor B and properdin have been observed in the resting zone of cartilage, and the alternative pathway likely plays a role in cartilage development.
=== Plasma cortisol concentration === Resting plasma cortisol may be slightly elevated in affected horses, but is commonly within normal limits or below normal. Additionally, elevations may occur secondary to stress, concurrent disease, and due to individual variation. Therefore, resting cortisol levels alone are not adequate to diagnose or rule out the presence of PPID.
The two substrates of this enzyme are L-arabinose and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are L-arabino-1,4-lactone, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-arabinose:NAD+ 1-oxidoreductase. This enzyme participates in ascorbate and aldarate metabolism.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。